An HPLC-UV method was developed and validated for the determination of lumefantrine in human plasma. Lumefantrine and its internal standard halofantrine were extracted from plasma samples using protein precipitation with acetonitrile (0.2% perchloric acid) followed by solid-phase extraction with Hypersep C(8) cartridges. Chromatographic separation was performed on a Zorbax SB-CN HPLC column (3.0 x 150 mm, 3.5 microm) with water/methanol (0.1% TFA) as the mobile phases in a gradient elution mode. Detection was performed using UV/vis detector at lambda = 335 nm. The method showed to be linear over a range of 50-10,000 ng/mL with acceptable intra- and inter-day precision and accuracy. The mean recoveries were 88.2% for lumefatrine and 84.5% for the I.S. The internal standard halofantrine is readily available from commercial sources. This method was successfully applied to a pharmacokinetic interaction study between a first-line antimalarial combination (artemether-lumefantrine) and antiretroviral therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865164 | PMC |
| http://dx.doi.org/10.4137/aci.s4431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low prevalence of copy number variation in pfmdr1 and pfpm2 in Plasmodium falciparum isolates from southern Angola.
Malar J
January 2025
Global Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Rua da Junqueira 100, 1349-008, Lisbon, Portugal.
Background: Malaria is the parasitic disease with the highest global morbidity and mortality. According to estimates from the World Health Organization (WHO), there were around 249 million cases in 2022, with 3.4% occurring in Angola.
View Article and Find Full Text PDFArtemether-lumefantrine-amodiaquine or artesunate-amodiaquine combined with single low-dose primaquine to reduce Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a five-arm, phase 2, single-blind, randomised controlled trial.
Lancet Microbe
December 2024
Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Background: Triple artemisinin-based combination therapies (TACTs) can delay the spread of antimalarial drug resistance. Artesunate-amodiaquine is widely used for uncomplicated Plasmodium falciparum malaria. We therefore aimed to determine the safety and efficacy of artemether-lumefantrine-amodiaquine and artesunate-amodiaquine with and without single low-dose primaquine for reducing gametocyte carriage and transmission to mosquitoes.
View Article and Find Full Text PDFPlasmodium falciparum with pfhrp2 and pfhrp3 gene deletions in asymptomatic malaria infections in the Lake Victoria region, Kenya.
Trop Med Health
December 2024
Department of Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Malaria rapid diagnostic tests (RDTs) targeting the Plasmodium falciparum histidine-rich protein 2 (PfHRP2) are widely used to diagnose P. falciparum infection. However, reports of P.
View Article and Find Full Text PDFMulti-method coamorphous systems of lumefantrine with alpha ketoglutaric acid: Comprehensive characterization, biological evaluation and stability analysis.
Int J Pharm
January 2025
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India. Electronic address:
Article Synopsis
- Researchers developed coamorphous systems (CAM) using lumefantrine (LMF) and alpha-ketoglutaric acid (KGA) to improve LMF's solubility and bioavailability through three distinct methods: liquid-assisted grinding, solvent evaporation, and quench-cooling.
- Testing via PXRD, DSC, and other techniques confirmed the successful amorphization and intermolecular interactions in these CAMs, along with simulations showing diverse molecular environments.
- The new CAMs significantly enhanced solubility (up to 14.73x), dissolution rates (up to 2.63x), and pharmacokinetics in living organisms (up to 10.86x), while also demonstrating anti-cancer
Congenital Plasmodium vivax in a 3-day-old neonate: a case report.
J Med Case Rep
November 2024
Department of Pediatrics and Neonatal Nursing, School of Nursing and Midwifery, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
Background: Congenital malaria is an uncommon clinical infectious disease caused by vertical transmission of parasites from mother to child during pregnancy or delivery and a positive blood smear of malaria in newborns from 24 hours to 7 days of life, associated with a high mortality rate if it is not diagnosed and treated early. We present an unusual case of a 4-day-old boy with Plasmodium vivax malaria from Gondar, Ethiopia, suspected mainly based on a positive maternal history of malaria attacks in the seventh month of gestation and cured with artemether-lumefantrine therapy. The newborn presented with a lack of sucking and a high-grade fever.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!